FDA 483 - Haw Par Healthcare Limited - August 19, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Haw Par Healthcare Limited, an OTC drug manufacturer in Singapore, revealed significant deficiencies across its quality, production, facilities, and laboratory control systems. The firm failed to adequately investigate out-of-specification results, lacked proper process and cleaning validations, and did not follow or contemporaneously document production procedures. Several observations, including issues with production documentation and hold times, were repeat findings from a previous inspection, indicating persistent non-compliance.
ID · 19fa39fa-eb0b-4a0d-9906-a57810ecacf5